Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cullinan Therapeutics, Inc. (Nasdaq: CGEM) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. These documents include Current Reports on Form 8-K, which Cullinan uses to report material events such as clinical data updates, financial results, regulatory milestones, and significant corporate actions related to its biopharmaceutical business.
For a clinical-stage company like Cullinan, SEC filings are a primary source of detail on the development of its T cell engager and targeted therapy programs. Recent 8-K filings describe updated Phase 1 data for CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including response rates, safety findings, and the impact of FDA Fast Track designation. Other filings summarize financial results, cash and investment levels, and expectations for cash runway under the company’s operating plan.
Filings may also reference Cullinan’s work in autoimmune diseases with CLN-978, a CD19xCD3 bispecific T cell engager, and its collaboration with Taiho Oncology and Taiho Pharmaceutical on zipalertinib (CLN-081/TAS6417), an EGFR inhibitor for non-small cell lung cancer. These reports can include information on clinical timelines, regulatory interactions, and program prioritization decisions, such as the discontinuation of certain assets or the termination of license agreements.
On Stock Titan, investors can review Cullinan’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, helping to interpret complex clinical and regulatory language. Users can monitor new 8-K submissions in real time and place them in context with the company’s broader pipeline and news flow, supporting deeper analysis of CGEM’s risk profile, development progress, and strategic direction.
Cullinan Therapeutics, Inc. received an amended Schedule 13G from Biotechnology Value Fund–affiliated entities reporting a large, primarily passive stake in its common stock. As of the close of business on December 31, 2025, the BVF funds and a managed account beneficially owned an aggregate of 5,918,481 shares of Cullinan common stock, or about 9.99% of the outstanding shares, including shares issuable from Series A preferred stock.
The BVF group holds 555,935 shares of Series A convertible preferred stock, which is convertible into 5,559,350 common shares at a 10:1 ratio, but a 9.99% “Conversion Blocker” currently limits conversion to 167,798 underlying shares. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Cullinan, characterizing the position as a passive investment.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an open-market sale of common stock. On February 12, 2026, she sold 416 shares of Cullinan Therapeutics, Inc. common stock at $12.03 per share.
According to the footnote, the sale was made to cover personal income tax obligations triggered by the vesting of restricted stock units. After this transaction, Michaelson directly beneficially owns 128,219 shares of Cullinan Therapeutics common stock.
The Vanguard Group reported beneficial ownership of 3,298,504 shares of Cullinan Therapeutics Inc common stock, representing 5.58% of the class. Vanguard has shared voting power over 377,729 shares and shared dispositive power over all 3,298,504 shares, with no sole voting or dispositive power.
The shares are held on behalf of Vanguard’s clients, who are entitled to dividends and sale proceeds, and no single other person has an interest exceeding 5% of the class. Vanguard states that the position was acquired and is held in the ordinary course of business and not for the purpose of influencing control of Cullinan Therapeutics.
Cullinan Therapeutics, Inc. insider trading report: Chief Scientific Officer Jennifer Michaelson reported a sale of company stock. On January 22, 2026, she sold 4,000 shares of Cullinan Therapeutics common stock at a price of $12.30 per share in an open-market transaction. The sale was carried out under a pre-established Rule 10b5-1 trading plan that was put in place on August 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, Michaelson directly beneficially owned 128,635 shares of Cullinan Therapeutics common stock.
Shareholder Jennifer Michaelson has filed a Rule 144 notice to sell up to 4,000 shares of common stock of the company trading under symbol CGEM. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC, with an aggregate market value of $46,400 based on the price used in the notice, and an approximate sale date of January 22, 2026 on the NASDAQ. The filing notes that these 4,000 shares were acquired as restricted stock units from the issuer on December 11, 2023.
The notice also lists recent sales over the past three months for Michaelson’s account, including transactions of 1,345 shares for $13,458.34, 995 shares for $11,840.50, 2,148 shares for $26,592.24, and 4,000 shares for $49,200. Some of these trades are identified as being made under a Rule 10b5-1 trading plan. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Cullinan Therapeutics reported preliminary cash, cash equivalents, short- and long-term investments, and interest receivable of $439.0 million as of December 31, 2025, and expects this cash runway to last into 2029 based on its current operating plan. The company emphasized that these figures are unaudited and may change once year-end financial closing procedures are complete.
Cullinan also outlined key 2026 milestones across its pipeline. For CLN-978 in multiple autoimmune diseases, it plans initial Phase 1 data readouts across rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's disease between the second and fourth quarters of 2026. Velinotamig entered a Phase 1 study in China in December 2025, with initial data expected in the fourth quarter of 2026 to support global development.
In oncology, CLN-049 received Fast Track designation for relapsed/refractory AML, with further dose escalation updates and expansion cohorts planned through 2026, including preparation for an expected pivotal trial. For zipalertinib, co-developed with Taiho, a rolling NDA for relapsed EGFR ex20ins NSCLC is underway, with NDA completion targeted for the first quarter of 2026 and Cullinan eligible for up to $130.0 million in U.S. regulatory milestones plus 50% of any future pre-tax U.S. profits.
Cullinan Therapeutics Chief Scientific Officer, a reporting officer of the company, disclosed small open-market stock sales in December 2025. On 12/12/2025, 2,148 shares of common stock were sold at $12.38 to cover personal income tax obligations related to vesting restricted stock units.
On 12/15/2025, 995 shares were sold at $11.90 under a pre-arranged trading plan established pursuant to Rule 10b5-1 on August 7, 2025. After these transactions, the officer beneficially owns 136,878 shares of common stock, including 2,017 shares purchased through the 2021 Employee Stock Purchase Plan for the purchase period from January 1, 2025 through June 30, 2025.
Cullinan Therapeutics, Inc. presented updated Phase 1 data for its bispecific antibody CLN-049 in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the ASH Annual Meeting. As of the August 2025 cutoff, 45 patients were enrolled across dose levels from 1.5 to 12 μg/kg, with 41 evaluable for efficacy. At the highest dose of 12 μg/kg (16 patients), the complete response/complete remission with partial hematologic recovery (CR/CRh) rate was 31% (5 of 16), and the composite complete response (CRc) rate was also 31%.
Across doses at or above 6 μg/kg (32 patients), the CR/CRh rate was 25% (8 of 32) and the CRc rate was 28% (9 of 32), with promising durability: 63% (5 of 8) of CR/CRh responders had responses lasting more than 16 weeks, and some proceeded to stem cell transplant. Among patients with bone marrow blasts under 5% at these doses, 30% were MRD negative, including one ongoing response beyond 36 weeks. In eight patients with high‑risk TP53‑mutated AML at 12 μg/kg, 50% achieved CR/CRh, with most responses lasting over 16 weeks. Safety data showed a favorable profile, with cytokine release syndrome mostly Grade 1–2, no Grade 3 CRS with two step‑up doses, and no CRS‑related treatment discontinuations. CLN-049 development will proceed under U.S. FDA Fast Track designation, with dose escalation ongoing and expansion cohorts planned in early 2026.
Cullinan Therapeutics, Inc. (CGEM)11/24/2025, the officer sold 4,000 shares of common stock at $12.3 per share in an open-market sale. After this trade, the officer beneficially owns 138,004 shares of Cullinan common stock. The filing notes that this sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on August 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Cullinan Therapeutics, through its subsidiary Cullinan Amber Corp., is ending development of its CLN-617 cancer immunotherapy program. On November 18, 2025, the company notified the Massachusetts Institute of Technology that it is terminating their Exclusive Patent License Agreement covering the technology behind CLN-617, with the termination effective February 18, 2026. Under that agreement, MIT had granted Cullinan exclusive worldwide rights to develop the CLN-617 technology, which will now be returned to MIT. This move confirms CLN-617 will no longer be advanced within Cullinan’s pipeline.